Genentech Stops Avastin Ovarian Cancer Trial Enrollment After GI Perforations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech is discontinuing enrollment of a Phase II study of Avastin (bevacizumab) in platinum-refractory ovarian cancer patients due to an excessively high rate of reported gastrointestinal perforations